Serine proteases, and specifically those expressed in prostate epithelium, have emerged as important molecules of relevance for understanding the pathophysiology and mechanisms of the prostate cancer metastatic process. Further, the enzymatic activities of these proteases when expressed in ectopic locations such as in the bone may alter the local environment to favor tumor cell invasion and growth.
The aims of this proposal are based upon the hypothesis that: Progression to metastatic prostate cancer is driven by the persistent in situ and ectopic expression of membrane-bound serine protease enzymes TMPRSS2, hepsin and matriptase. These serine proteases influence metastatic disease through protease action on barriers to invasion (e.g. extracellular matrix) and reciprocal alterations in signaling factors derived from the tumor and microenvironment (e.g. IGF, HGF, CXCL12).
The specific aims of this proposal are:
Aim 1. Define the biological substrates of the TMPRSS2 protease, compare the substrate specificities with hepsin (and other proteases), and identify inhibitors of TMPRSS2 function (Collaboration wth Project 3).
Aim 2. Determine the cellular signaling pathways influenced by TMPRSS2 activity and identify the attendant phenotypic responses that modulate tumorigenic characteristics of proliferation, migration, and invasion. Initial studies will focus on IGF, HGF, and CXCL12 signaling. (Collaboration with Project 3).
Aim 3. Determine the biological role(s) and molecular mechanisms by which TMPRSS2 influences prostate cancer cell dissemination and growth in the bone environment (Collaboration with Project 1). Completing the specific aims of this proposal will determine mechanisms by which TMPRSS2 influences prostate cancer cell invasion and metastasis, and will develop model systems and reagents suitable for exploiting TMPRSS2 as a therapeutic target.

Public Health Relevance

The lethal form of prostate cancer manifests as disseminated disease to bone and other sites. We have determined that a membrane-anchored serine protease, TMPRSS2, modulates features of prostate cancer metastasis. This proposal is designed to determine the mechanisms by which TMPRSS2 contributes to invasive and metastatic growth, and identify inhibitors capable of abrogating TI /IPRSS2 function.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA085859-07
Application #
8120390
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
7
Fiscal Year
2010
Total Cost
$580,187
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Montgomery, Bruce; Tretiakova, Maria S; Joshua, Anthony M et al. (2017) Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res 23:2169-2176
Martin, P L; Yin, J-J; Seng, V et al. (2017) Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer. Oncogene 36:525-533
Suominen, Mari I; Fagerlund, Katja M; Rissanen, Jukka P et al. (2017) Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23:4335-4346
Don-Doncow, Nicholas; Marginean, Felicia; Coleman, Ilsa et al. (2017) Expression of STAT3 in Prostate Cancer Metastases. Eur Urol 71:313-316
Wu, Yu; Schoenborn, Jamie R; Morrissey, Colm et al. (2016) High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn 18:131-43
Morrissey, Colm; Vessella, Robert L; Lange, Paul H et al. (2016) The biology and clinical implications of prostate cancer dormancy and metastasis. J Mol Med (Berl) 94:259-65
Roudier, Martine P; Winters, Brian R; Coleman, Ilsa et al. (2016) Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate 76:810-22
Henzler, Christine; Li, Yingming; Yang, Rendong et al. (2016) Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7:13668
Kumar, Akash; Coleman, Ilsa; Morrissey, Colm et al. (2016) Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22:369-78
Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81

Showing the most recent 10 out of 157 publications